-
I’m looking to better understand the side effects reported for childhood vaccines in the UK and was hoping you could point me in the right direction. Do you have a summary or any data on what’s been reported through the Yellow Card scheme for each vaccine please? I’m particularly interested in how common the different reactions are and whether there’s any analysis or commentary available from the MHRA. Also, my son has a rare ectopic heartbeat condition, and as far as I'm aware I can't see any research on whether vaccines can lead to more severe reactions in babies who have this condition - hence my hesitancy. If there’s a public dashboard or report that covers this, a link would be really helpful. Thanks in advance for your help
Published: 12 August 2025
-
I am writing to make a request for information under the Freedom of information Act 2000. We operate the website nupex.co.uk, which was recently suspended by our domain registrar, 123 Reg, who advised us that the suspension was carried out at the instruction of the Criminal Enforcement Unit of the MHRA. We have not received any direct communication from the MHRA explaining the reasons for this intervention or outlining Legal basis or supporting evidence. Accordingly, we request the following information: Request for information: 1. A copy of any and all correspondence between the MHRA (including the Criminal Enforcement Unit) and123Reg concerning the domain nupex.co.uk 2. A copy of any internet reports, memoranda, meeting minutes, or communications discussing or authorising enforcement action against the said domain. 3. Any evidence, complaints, or third-party submissions that contributed to the decision to request the domain suspension. 4. The name and department of the officer or team who authorised or signed off the instruction. 5. Any documented policies or Internal guidelines followed in issuing takedown requests of this nature. 6. Details of any complaints, adverse incident reports, or investigations specifically related to our website or company.
Published: 12 August 2025
-
I am writing under the provisions of the Freedom of Information Act 2000 to request information held by the Medicines and Healthcare products Regulatory Agency (MHRA) concerning the marketing authorisations of the following pharmaceutical products: Product MAH PL Stugeron 15mg Tablets Janssen-Cilag/McNeil PL 15513/0349 Cinnarizine 15mg Tablets Mylan PL 04569/0476 PL 04569/0599 Specifically, I am requesting the release of non-confidential regulatory and technical information available within the marketing authorisation dossiers, as detailed below: Source of information Current Information required Module 2 All sections of this Module - From 2.5 to 2.7.6 I acknowledge that certain parts of this information may fall under exemptions per Sections 41 (Information provided in confidence) or 43 (Commercial interests) of the Freedom of Information Act.
Published: 12 August 2025
-
Please could you provide the currently approved pdf artwork mock up of the outer label/carton and inner label of the product TAGRISSO 80 mg Tablets, under licence number PLGB 17901-0341. I have attached the current SPC to confirm the licence details.
Published: 12 August 2025
-
Please could you provide the currently approved pdf artwork mock up of the outer label/carton and inner label of the product KYPROLIS 60 mg powder for solution for infusion, under licence number PLGB 13832-0025. I have attached the current SPC to confirm the licence details.
Published: 12 August 2025
-
Please can you provide the safety data and clinical trial data that supports giving pregnant women the experimental mRNA covid 19 vaccinations. Please provide specific references to the original trial data that showed that the mRNA vaccinations were trailed on pregnant women, the outcomes and how they have since been deemed to be both safe and effective.
Published: 12 August 2025
-
Please could you provide the currently approved pdf artwork mock up of the outer label/carton and inner label of the product VERZENIOS 100 mg film-coated tablets, under licence number PLGB 14895-0264. I have attached the current SPC to confirm the licence details.
Published: 12 August 2025
-
When time permits, would you please provide the post-inspection reports related to the following inspections: QUANTUM PHARMACEUTICAL LIMITED, located at UNIT 26, 9 HERON ROAD, HARBOUR COURT, BELFAST, BT3 9HB, UNITED KINGDOM, (INSP), Inspection End Date: 27-Mar-25, INSP GDP 21923/37422852-0002 GENECINE LTD, located at UNIT 13, REDLANDS CENTRE, REDLANDS, COULSDON, CR5 2HT, UNITED KINGDOM, (INSP), Inspection End Date: 5-Feb-25, INSP GDP 53736/19513541-0001 MODERNA BIOTECH MANUFACTURING UK LTD, located at PERIMETER ROAD, HARWELL OXFORD, DIDCOT, OX11 0GN, UNITED KINGDOM, (INSP), Inspection End Date: 31-Jan-25, INSP GMP 60304/37421606-0001 SPECTRUMX DIRECT LIMITED, located at UNIT 8 NOVUS PARK, HAIG ROAD, KNUTSFORD, WA16 8FB, UNITED KINGDOM, (INSP), Inspection End Date: 16-Jan-25, INSP GDP 59246/36225094-0002 RX EXTRACTION LTD, located at UNIT 10 ROWAN TRADE PARK, NEVILLE ROAD, BRADFORD, BD4 8TQ, UNITED KINGDOM, (INSP), Inspection End Date: 12-Dec-24, INSP GMP 55932/25925977-0002 GLAXO OPERATIONS UK LIMITED, located at PRIORY STREET, WARE, SG12 0DJ, UNITED KINGDOM, (INSP), Inspection End Date: 6-Dec-24, INSP GMP/GDP 4/15159-0034 BRISTOL LABORATORIES LIMITED, located at UNIT 6, SOVEREIGN PARK, LAPORTE WAY, LUTON, LU4 8EL, UNITED KINGDOM, (INSP), Inspection End Date: 14-Nov-24, INSP GDP 17907/10438142-0005 CHARLES RIVER LABORATORIES EDINBURGH LIMITED, located at ELPHINSTONE RESEARCH CENTRE, TRANENT, EH33 2NE, UNITED KINGDOM, (INSP), Inspection End Date: 14 November 2024, INSP GLP 1634/25448-0041
Published: 12 August 2025
-
This is a request under FOIA for details of instances in which Medicines and Healthcare products Regulatory Agency (including, where applicable, any agencies, bodies, or units for which it is ultimately responsible for supplier payments) has failed to pay its suppliers on time, thereby causing liabilities for late payment compensation and/or interest on late payments to be incurred for the public purse. As the Government has made clear, late payment remains a significant issue for business and a drag on the UK economy as a whole. It is clear that, despite what the law says, many suppliers have not received timely payment or the interest and compensation for late payment to which they are entitled by statute. Public authorities must keep information on payment in order to comply with their legal obligations, and there is a public interest in ensuring both compliance and that unpaid interest and compensation is recovered from public authorities. If proper records are kept as they ought to be, then information in this respect ought readily to be available. The information requested below is not confidential, and its disclosure under FOIA is not capable of adversely affecting any party’s commercial interests. This is because this request is aimed at data about late payment liabilities that have in fact arisen: the disclosure of this data cannot cause any additional liability to arise. We therefore do not anticipate any reasonable grounds for refusing this request.
Published: 12 August 2025
-
I am requesting information under a Freedom of Information Request in relation to the number and detail of complaint regarding the Depo Provera Contraceptive Injection. The information I would like to know is: • How many complaints have been made in relation to the Depo Provera. • What side effects have been reported within those reports.
Published: 12 August 2025
